Clinical News

Survey uncovers lupus corticosteroid treatment issuesPatients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
Drug shortage help on horizon
Drug shortage help on horizonWhile hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
New treatment for advanced kidney cancer approved
New treatment for advanced kidney cancer approvedFDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
FDA approves first once-monthly injection for opioid abuseSoon after FDA approved a novel device to treat opioid use disorder, FDA approved the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder (OUD).
FDA clears first opioid withdrawal deviceFDA granted a new indication to a device that can help reduce the symptoms of withdrawal from the prescription pain drugs.
How hospitals can cope with IV drug shortagesBecause of the impact of Hurricanes Maria and Irma on Puerto Rico’s infrastructure and drug manufacturing, hospitals face an ongoing shortage of IV fluids manufactured there.
FDA approves first pill that can be tracked when ingestedFDA approved the first drug in the United States that has a digital ingestion tracking system, which records when the medication was taken.
Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
FDA issues warning over marijuana products claiming cancer cure
FDA issues warning over marijuana products claiming cancer cureFDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.
Game-changing hep B vaccine gets FDA nodThe first 2-dose hepatitis B vaccine, which was recently approved by FDA, is expected to be commercially available in early 2018.